Compare GSK plc (GSK) vs AT&T Inc. (T) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs AT&T Inc. — how do they compare? GSK plc trades at $46.65 (market cap $91.88B), while AT&T Inc. trades at $22.07 (market cap $170.42B). The key difference: AT&T Inc. is the larger of the two by market cap, and AT&T Inc. pays the higher dividend (4.46%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and AT&T Inc. for 118 Days on average.
| GSK | T | |
|---|---|---|
Market Cap | $91.88B | $170.42B |
Volume | 7,730,529 | 50,780,036 |
Sector | Health | Media |
52-Week High | $61.18 | $29.10 |
52-Week Low | $43.24 | $20.49 |
Typical Hold Time | 93 Days | 118 Days |
Enterprise Value | $111.88B | $315.74B |
Dividend Yield | 3.9% | 4.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
AT&T (T) trades at $22.105, down 9.68% in the last session, reflecting market concerns despite strong fundamentals. The stock shows solid profitability with 16.94% net margin and attractive valuation at 8.21 P/E. Recent earnings beats and a $3 billion fiber deal with Corning highlight growth initiatives, while technical indicators show mixed signals with RSI at neutral levels.
The outlook remains balanced with analyst consensus at $27.50 target suggesting 24% upside, supported by fiber expansion and wireless growth. Key risks include heavy debt load at $118.44 billion and competitive pressures. The 4% dividend yield provides income support, but investors should monitor execution on debt reduction and revenue trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →
